Who is this for?
This is for people with advanced (metastatic or unresectable) melanoma — the most serious form of skin cancer — who are starting their first drug treatment.
Not long ago, this was one of the grimmest diagnoses in cancer: average survival was under a year, and only about 1 in 10 people were alive at five years. This trial is a big part of why that changed.
What kind of trial is this?
CheckMate 067 was a large phase III randomized trial — the most rigorous kind — with three groups: the two-immunotherapy combination, one immunotherapy alone (nivolumab), and an older immunotherapy alone (ipilimumab). The results here come from the 4-year follow-up, which is what proved the benefit lasts.
Background: from months to years
Melanoma turned out to be one of the cancers most responsive to immunotherapy. Ipilimumab (an anti-CTLA-4 drug) was the first to show some people could live much longer; then nivolumab (anti-PD-1) proved even more effective. CheckMate 067 asked the natural next question: does combining the two do better still — and does the benefit last?
The trial: what was tested and how
CheckMate 067 enrolled 945 people with untreated advanced melanoma, randomly assigned to one of three treatments:
- Nivolumab + ipilimumab (314 people): the two immunotherapy drugs together, then nivolumab alone.
- Nivolumab alone (316 people).
- Ipilimumab alone (315 people): the older single immunotherapy.
The main measures were how long the cancer was held in check (progression-free survival) and how long people lived (overall survival).
Results: what they found
Both nivolumab-containing treatments dramatically outlived the older drug alone, and the survival curves flattened into a long-term plateau — the signature of durable, immunotherapy-driven remission.
4-year outcomes in advanced melanoma
More than half of people on the combination were alive at 4 years (nivolumab alone: 46%) — a 46% lower risk of death versus the older drug (HR 0.54). In a cancer where 5-year survival was once about 10%.
So many people on the combination were still alive that the “median” survival hadn’t been reached — and the survival curve had flattened into a durable plateau.
The combination is powerful but demanding: serious immune-related side effects occurred in over half of people. Nivolumab alone was far gentler while still highly effective — which is why the choice is individualized.
How big a change was this, really?
Enormous. Before immunotherapy, advanced melanoma had an average survival of well under a year and a 5-year survival around 10%. With these treatments, roughly half of people are alive at 4 years and beyond — and the flat “tail” of the survival curve means some are effectively in long-term remission. It is one of the clearest examples of immunotherapy transforming a once-lethal cancer.
Two immunotherapy drugs, or one?
The combination is the most effective but causes serious side effects in about half of people; nivolumab alone is gentler (about 22%) and still works very well. Newer options, such as relatlimab + nivolumab, aim for a middle ground — more effective than one drug, less toxic than the ipilimumab combination. The right choice depends on how aggressive the disease is and a person’s ability to tolerate side effects.
What does the “plateau” mean?
On a survival graph, immunotherapy curves often stop falling and level off — a plateau. It reflects a group of people whose cancer is controlled for the long term, sometimes even after treatment is stopped. Longer follow-up of this trial has confirmed that the plateau holds for years, which is why doctors talk about the possibility of durable, long-term remission in melanoma.
The bottom line
For advanced melanoma, CheckMate 067 showed that immunotherapy — especially two drugs together — can turn a cancer once survivable only for months into one where more than half of people are alive years later. The two-immunotherapy combination gave the best survival (53% at 4 years) but caused serious side effects in about half of people; nivolumab alone was gentler and still very effective. The flat “tail” of the survival curve — durable, lasting remission — is what makes this a landmark.
What this could mean for you
- Immunotherapy is the foundation. For advanced melanoma, immunotherapy — one drug or two — is the standard first treatment.
- Durable remission is a real possibility. Unlike treatments that only work temporarily, these can produce years-long remissions.
- One drug or two is a real decision. The combination is more powerful but harder to tolerate; nivolumab alone (or a newer combination) may suit some people better.
- Report side effects early. Immune-related effects can appear anywhere in the body and are far easier to manage when caught early.
Questions & comments
Have a question about this research? Ask below. Questions are read and answered by the site. We can’t give personal medical advice, but we’re glad to explain the research more clearly.